On this page

PROCTOFOAM

pramoxine hydrochloride hydrocortisone acetate · Aerosol, Foam

Prescription ANDA TE BX RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
PROCTOFOAM HC
Generic name
pramoxine hydrochloride hydrocortisone acetate
Dosage form
Aerosol, Foam
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Viatris Specialty LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
2
Packages
2
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone Acetate 100 mg/10g 1291082 View
Pramoxine Hydrochloride 100 mg/10g 1234532 View
Pramoxine Hydrochloride 150 mg/15g 1234532 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Aerosol, Foam
Route of administration
Topical
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
086195
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 26, 1978
Sponsor
MYLAN SPECIALITY LP
Products on application
1
Submissions recorded
30
Products approved under application 086195.
Product Trade name Form Strength Ingredient Status TE Flags
086195-001 PROCTOFOAM HC AEROSOL, METERED HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE Prescription BX RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
BX
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Bioequivalence NOT established — insufficient data to determine equivalence

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 086195.
Type No. Action Status Date Review
Supplement 52 Manufacturing (CMC) Approved January 21, 2021 Unknown
Supplement 38 Labeling Approved December 6, 2004 —
Supplement 40 Labeling Approved August 11, 2003 —
Supplement 37 Labeling Approved August 11, 2003 —
Supplement 39 Manufacturing (CMC) Approved January 3, 2003 —
Supplement 36 Manufacturing (CMC) Approved April 21, 2000 —
Supplement 35 Manufacturing (CMC) Approved November 29, 1999 —
Supplement 34 Manufacturing (CMC) Approved January 12, 1999 —
Supplement 32 Manufacturing (CMC) Approved August 7, 1998 —
Supplement 33 Manufacturing (CMC) Approved May 7, 1998 —
Supplement 31 Labeling Approved February 25, 1998 —
Supplement 30 Manufacturing (CMC) Approved February 25, 1998 —
Supplement 29 Manufacturing (CMC) Approved February 25, 1998 —
Supplement 28 Manufacturing (CMC) Approved August 11, 1997 —
Supplement 27 Manufacturing (CMC) Approved June 3, 1997 —
Supplement 25 Manufacturing (CMC) Approved February 28, 1997 —
Supplement 24 Labeling Approved January 26, 1995 —
Supplement 23 Manufacturing (CMC) Approved November 16, 1994 —
Supplement 22 Labeling Approved January 30, 1991 —
Supplement 21 Labeling Approved August 28, 1990 —
Supplement 20 Labeling Approved February 8, 1989 —
Supplement 15 Manufacturing (CMC) Approved December 9, 1985 —
Supplement 10 Manufacturing (CMC) Approved July 8, 1983 —
Supplement 11 Manufacturing (CMC) Approved September 1, 1982 —
Supplement 8 Manufacturing (CMC) Approved May 27, 1982 —
Supplement 9 Manufacturing (CMC) Approved April 30, 1982 —
Supplement 6 Manufacturing (CMC) Approved April 30, 1982 —
Supplement 5 Manufacturing (CMC) Approved April 30, 1982 —
Supplement 4 Manufacturing (CMC) Approved April 30, 1982 —
Original application 1 Approved July 26, 1978 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250815). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN OTC DRUG · 20250815 HUMAN PRESCRIPTION DRUG · 20250415

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Proctofoam ® HC is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the anal region.

Purpose Local anesthetic

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply to affected area 3 to 4 times daily. Use the applicator supplied for anal administration. For perianal use, transfer a small quantity to a tissue and rub in gently. Directions for Use. 1. Attach Cap: Place cap on top of container. 2. Shake Container: Shake foam container vigorously for 5-10 seconds before each use. Do not remove container cap during use of the product. 3. Attach Applicator: Hold container upright on a level surface and gently place the tip of the applicator onto the nose of the container cap. CONTAINER MUST BE HELD UPRIGHT TO OBTAIN PROPER FLOW OF MEDICATION. 4. Pull Plunger: Pull plunger past the fill line on the applicator barrel. 5. Prime Container: Hold the container and applicator at eye level. Place the index and middle fingers on the container cap flanges and the thumb beneath the container. Support the applicator with your other hand. Prime the container by pressing down firmly on flanges and then release. With initial priming, a burst of air may come out of the container. It usually requires 1-2 pumps for foam to appear. 6. Fill Applicator: To fill applicator barrel, press down firmly on cap flanges, hold for 1-2 seconds, and release. Wait 5-10 seconds to allow foam to expand in applicator barrel. Repeat until foam reaches fill line. It usually requires 3-4 pumps for foam to reach fill line. Remove applicator from container cap. Note: If foam goes beyond fill line, it will continue to expand and flow backwards resulting in foam build-up under cap. 7. Foam Application: Hold applicator firmly by barrel, making sure thumb and middle finger are positioned securely underneath and resting against barrel wings. Place index finger over the plunger. Gently insert tip into anus. Once in place, push plunger to expel foam, then withdraw applicator. CAUTION: Do not insert any part of the aerosol container directly into the anus. Apply to anus only with enclosed applicator. Do not insert any part of the applicator past the anus into rectum. 8. Clean Applicator: After each use, applicator parts should be pulled apart for thorough cleaning with warm water. Since some foam will appear under the cap, the cap and underlying tip should be pulled apart and rinsed to help prevent build-up of foam and possible blockage.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroid products are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Warnings For external use only When using this product • do not exceed the recommended daily dosage unless directed by a doctor • do not put this product into the rectum by using fingers or any mechanical device or applicator • do not insert any part of the aerosol container into the rectum Stop use and ask a doctor if • rectal bleeding occurs • condition worsens or does not improve within 7 days • allergic reaction occurs to the ingredients in this product • symptom being treated does not subside • redness, irritation, swelling, pain or other symptoms develop or increase If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-866-210-5948 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Proctofoam ® HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) is a topical aerosol foam for anal use containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% in a hydrophilic base containing cetyl alcohol, emulsifying wax, methylparaben, poly-oxyethylene-10-stearyl ether, propylene glycol, propylparaben, purified water, trolamine and inert propellants: isobutane and propane. Proctofoam ® HC contains a synthetic corticosteroid used as an anti-inflammatory/antipruritic agent and a local anesthetic. Hydrocortisone acetate Molecular weight: 404.50. Solubility of hydrocortisone acetate in water: 1 mg/100 mL. Chemical name: pregn-4-ene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-,(11β)-. Pramoxine hydrochloride Molecular weight: 329.86. Pramoxine hydrochloride is freely soluble in water. Chemical name: morpholine, 4-[3-(4-butoxyphenoxy) propyl]-, hydrochloride. Hydrocortisone Acetate Structural Formula Pramoxine Hydrochloride Structural Formula

Active Ingredient

openFDA Drug Labeling

Active ingredient Pramoxine hydrochloride 1%

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS .)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Proctofoam ® HC is supplied in an aerosol container with a special anal applicator. When used correctly, the aerosol container will deliver a minimum of 14 applications. NDC 0037-6822-10 10 g Store upright at controlled room temperature 20°-25°C (68°-77°F). DO NOT REFRIGERATE. Distributed by: Meda Pharmaceuticals Inc. Canonsburg, PA 15317 U.S.A. © 2025 Viatris Inc. PROCTOFOAM is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. IN-682210-05 141371-0421

Adverse event reports

Source: openFDA FAERS
73,232
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II February 2, 2022 Mylan Pharmaceuticals Inc cGMP deficiencies Terminated
Class II June 2, 2021 Cardinal Health Inc. CGMP Deviations: Intermittent exposure to temperature excursion during storage. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0037-6822-10 0037-6822 Viatris Specialty LLC 1 CANISTER in 1 CARTON (0037-6822-10) / 10 g in 1 CANISTER August 15, 2014
0037-6823-15 0037-6823 Viatris Specialty LLC 1 CANISTER in 1 CARTON (0037-6823-15) / 15 g in 1 CANISTER August 18, 2014
0037-6822 0037-6822 Viatris Specialty LLC — August 15, 2014
0037-6823 0037-6823 Viatris Specialty LLC — August 18, 2014

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 12 sections on this page.